• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.

作者信息

Genestreti Giovenzio, de Biase Dario, Di Battista Monica, Cavallo Giovanna, Degli Esposti Roberta, Visani Michela, Acquaviva Giorgia, Brand Thomas, Pession Annalisa, Tallini Giovanni, Brandes Alba A

机构信息

Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy.

Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.

出版信息

Clin Lung Cancer. 2017 May;18(3):e215-e217. doi: 10.1016/j.cllc.2017.01.003. Epub 2017 Jan 11.

DOI:10.1016/j.cllc.2017.01.003
PMID:28162944
Abstract
摘要

相似文献

1
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Clin Lung Cancer. 2017 May;18(3):e215-e217. doi: 10.1016/j.cllc.2017.01.003. Epub 2017 Jan 11.
2
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.在携带吉非替尼敏感突变L858R的初治肺腺癌中获得性表皮生长因子受体（EGFR）吉非替尼耐药突变
PLoS Med. 2005 Sep;2(9):e269. doi: 10.1371/journal.pmed.0020269. Epub 2005 Sep 27.
3
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.一线吉非替尼对非亚裔表皮生长因子受体（EGFR）突变肺腺癌患者疗效显著。
Onkologie. 2010;33(5):231-8. doi: 10.1159/000302729. Epub 2010 Apr 9.
4
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.比较表皮生长因子受体外显子 19 或 21 突变的非小细胞肺癌患者使用吉非替尼和厄洛替尼治疗的临床结局。
J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
5
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌中的原发性酪氨酸激酶抑制剂（TKI）耐药性：一个悬而未决的问题。
Tumori. 2015 Jul 24;101(4):e115-7. doi: 10.5301/tj.5000317.
6
Two rare exon 21 EGFR mutations in patients treated with gefitinib.两名接受吉非替尼治疗的患者出现罕见的外显子21表皮生长因子受体（EGFR）突变。
J Thorac Oncol. 2013 Apr;8(4):e36-7. doi: 10.1097/JTO.0b013e318286cf9e.
7
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.表皮生长因子受体（EGFR）第19外显子的一种罕见插入突变在酪氨酸激酶抑制剂（TKI）治疗后显示疾病稳定。
J Thorac Oncol. 2013 Dec;8(12):e107-8. doi: 10.1097/JTO.0b013e3182a471e0.
8
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.19号外显子EGFR发生罕见插入突变的肺腺癌对吉非替尼部分缓解：一例报告
Exp Oncol. 2017 Jul;39(2):155-156.
9
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.来自胸腔积液的肿瘤源性DNA中的表皮生长因子受体（EGFR）突变状态是预测吉非替尼疗效的实际依据。
Br J Cancer. 2006 Nov 20;95(10):1390-5. doi: 10.1038/sj.bjc.6603428. Epub 2006 Oct 24.
10
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.中国非小细胞肺癌患者表皮生长因子受体酪氨酸激酶结构域的吉非替尼敏感突变
Clin Cancer Res. 2005 Jun 15;11(12):4289-94. doi: 10.1158/1078-0432.CCR-04-2506.

引用本文的文献

1
Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinomas: A Single Center Study from Iran.肺腺癌中的表皮生长因子受体突变：来自伊朗的一项单中心研究
Asian Pac J Cancer Prev. 2018 Jan 27;19(1):111-114. doi: 10.22034/APJCP.2018.19.1.111.